Ratnakar Securities Pvt. Ltd.

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private

BSE6254.8531.5 (+0.51 %)

PREV CLOSE ( ) 6223.35

OPEN PRICE ( ) 6350.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 790

TODAY'S LOW / HIGH ( )6198.00 6350.00

52 WK LOW / HIGH ( )2603.2 7794

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984

Management Info

Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director

Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

10May Resignation of Statutory Auditor
Inter alia, approved:- 1. Recommended payment of final dividend of Rs..

30Apr Neuland Laboratories informs about ear
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

03Apr Neuland Laboratories informs about cer
Neuland Laboratories has informed that it enclosed certificate as requir..

04Mar Neuland Laboratories informs about ana
Neuland Laboratories has informed that the Companyâ€™s management will b..

Financials

in Millions

	QTR Mar 24	ANNUAL 24
Net Profit	676.06	2995.96
Gross Profit	920.8	4007.69
Operating Profit	1121.51	4744.65
Net Sales	3850.1	15585.8

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE) 8857.55 (3.35%)	M.Cap ( in Cr)20379.80
Glaxosmithkline Phar (BSE) 2291.55 (13.23%)	M.Cap ( in Cr)38820.24
Alkem Laboratories (BSE) 5440.25 (2.32%)	M.Cap ( in Cr)65139.01
Astrazeneca Pharma I (BSE) 5757.75 (2.10%)	M.Cap ( in Cr)14087.13
Pfizer (BSE) 4403.65 (1.56%)	M.Cap ( in Cr)20088.52

Shareholding Pattern

	NON-INSTITUTION	35.88%
	PROMOTERS	32.74%
	MUTUAL FUNDS/UTI	3.88%
	GOVERNMENT	0.4%
	FI/BANKS/INSURANCE	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
WOC Pharma and Heal...	2.83
HSBC Small Cap Fund...	1.37
HSBC Multi Cap Fund...	1.01
Motilal Oswal Nifty...	1.00
Bajaj Finserv Flexi...	0.91
Bandhan Small Cap F...	0.74

attention investors
kyc
ipo
ibt trading

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

NEULAND LABORATORIES LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES